AIM To compare therapeutic outcomes and adverseevents in initial solitary hepatocellular carcinoma（HCC） treated with radiofrequency ablation （RFA） andCyberKnife？.METHODS： Seventy three consecutive patients withi...AIM To compare therapeutic outcomes and adverseevents in initial solitary hepatocellular carcinoma（HCC） treated with radiofrequency ablation （RFA） andCyberKnife？.METHODS： Seventy three consecutive patients withinitial solitary HCC treated with RFA （38 patients;RFA group） and CyberKnife （35 patients; CK group）were enrolled in this study. Background factorswere compared between the two groups. Local andintrahepatic distant recurrence control, and cumulativesurvival rates were compared between the two groups.These were determined using the Kaplan-Meier method,and the significance of differences was analyzed by log-rank test. The presence of more grade 3 on CTCAE ver.4.0 early and late adverse events was investigated.RESULTS： In background factors, age was significantlyhigher （P = 0.005） and the tumor diameter wassignificantly larger （P = 0.001） in the CK group. The1-year local recurrence control rates were 97.4%and 97.1% in the RFA and CK groups, respectively （P= 0.71）; the 1-year intrahepatic distant recurrencecontrol rates were 85.6% and 86.1%, respectively （P= 0.91）; and the 1-year cumulative survival rates were100% and 95.2%, respectively （P = 0.075）, showingno significant difference in any rate between the twogroups. There were no late adverse event in the RFAgroup, but 11.4% in the CK group had late adverseevents. In the CK group, the Child-Pugh score at 12 moafter treatment was significantly higher than that in theRFA group （P = 0.003） and significantly higher than thescore before treatment （P = 0.034）.CONCLUSION： The occurrence of adverse events is aconcern, but CyberKnife treatment is likely to becomean important option for local treatment of early HCC.展开更多
文摘AIM To compare therapeutic outcomes and adverseevents in initial solitary hepatocellular carcinoma（HCC） treated with radiofrequency ablation （RFA） andCyberKnife？.METHODS： Seventy three consecutive patients withinitial solitary HCC treated with RFA （38 patients;RFA group） and CyberKnife （35 patients; CK group）were enrolled in this study. Background factorswere compared between the two groups. Local andintrahepatic distant recurrence control, and cumulativesurvival rates were compared between the two groups.These were determined using the Kaplan-Meier method,and the significance of differences was analyzed by log-rank test. The presence of more grade 3 on CTCAE ver.4.0 early and late adverse events was investigated.RESULTS： In background factors, age was significantlyhigher （P = 0.005） and the tumor diameter wassignificantly larger （P = 0.001） in the CK group. The1-year local recurrence control rates were 97.4%and 97.1% in the RFA and CK groups, respectively （P= 0.71）; the 1-year intrahepatic distant recurrencecontrol rates were 85.6% and 86.1%, respectively （P= 0.91）; and the 1-year cumulative survival rates were100% and 95.2%, respectively （P = 0.075）, showingno significant difference in any rate between the twogroups. There were no late adverse event in the RFAgroup, but 11.4% in the CK group had late adverseevents. In the CK group, the Child-Pugh score at 12 moafter treatment was significantly higher than that in theRFA group （P = 0.003） and significantly higher than thescore before treatment （P = 0.034）.CONCLUSION： The occurrence of adverse events is aconcern, but CyberKnife treatment is likely to becomean important option for local treatment of early HCC.
